Xenetic Biosciences, Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2021
August 12, 2021 at 09:31 pm
Share
Xenetic Biosciences, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was USD 287,603 compared to USD 112,927 a year ago. Operating loss was USD 1.127 million compared to USD 982,459 a year ago. Net loss was USD 1.106 million compared to USD 953,642 a year ago. Basic loss per share from continuing operations was USD 0.13 compared to USD 0.15 a year ago. For the half year, total revenue was USD 478,819 compared to USD 169,676 a year ago. Operating loss was USD 2.496 million compared to USD 2.213 million a year ago. Net loss was USD 2.452 million compared to USD 2.133 million a year ago. Basic loss per share from continuing operations was USD 0.28 compared to USD 0.34 a year ago.
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the development of its DNase platform toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic cancer, which includes pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma (CRC) and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the available therapeutic options.
XENETIC BIOSCIENCES, INC. 
